METTL14 and acute lymphoblastic leukemia: Using single nucleotide polymorphism (SNP) analysis, they found that METTL3 and METTL14 gene polymorphisms can elevate the risk of developing P-ALL, suggesting that their genetic polymorphisms may be potential biomarkers for P-ALL susceptibility and selection of oncologic chemotherapeutic drugs.